Sponsor

Cytokinetics

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Cytokinetics appears in 23 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials23
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

23 shown
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEFNCT06793371 · lead sponsor · 2025-02-06
RECRUITING
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionNCT06736574 · lead sponsor · 2024-12-19
RECRUITING
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT04944784 · lead sponsor · 2021-08-16
TERMINATED
Omecamtiv Mecarbil Post-trial Access StudyNCT04464525 · lead sponsor · 2020-12-18
WITHDRAWN
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart FailureNCT03759392 · lead sponsor · 2019-04-09
COMPLETED
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT03160898 · lead sponsor · 2017-07-24
COMPLETED
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329 · lead sponsor · 2017-01-06
COMPLETED
Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection FractionNCT02695420 · lead sponsor · 2016-04-14
COMPLETED
Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese AdultsNCT02601001 · lead sponsor · 2015-11-13
COMPLETED
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a YearNCT02496767 · lead sponsor · 2015-09-03
COMPLETED
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart FailureNCT01786512 · lead sponsor · 2013-02-26
COMPLETED
Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal InsufficiencyNCT01737866 · lead sponsor · 2012-11-01
COMPLETED
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)NCT01709149 · lead sponsor · 2012-10-01
COMPLETED
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)NCT01378676 · lead sponsor · 2011-06-01
COMPLETED
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)NCT01300013 · lead sponsor · 2011-04-01
COMPLETED
Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure PatientsNCT01077167 · lead sponsor · 2010-07-01
WITHDRAWN
Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart FailureNCT00941681 · lead sponsor · 2009-04-01
COMPLETED
Phase II Study of the Effect of CK-1827452 Injection on Myocardial EfficiencyNCT00748579 · lead sponsor · 2008-09-01
TERMINATED
PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and AnginaNCT00682565 · lead sponsor · 2008-04-01
COMPLETED
A Study of Ispinesib in Metastatic Breast CancerNCT00607841 · lead sponsor · 2007-12-01
TERMINATED
A Study of CK-1827452 Infusion in Stable Heart FailureNCT00624442 · lead sponsor · 2007-04-01
COMPLETED
A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy VolunteersNCT01380223 · lead sponsor · 2005-08-01
COMPLETED
A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary DiseaseNCT02662582 · collaborator · 2016-06-30
COMPLETED

Drugs studied in this sponsor's trials

2 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Cytokinetics as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo12
riluzole1

Sponsor roles

lead sponsor22
collaborator1
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.